Fiche centre
Stanford University Medical Center
Stanford — United States
Essais liés4clinical trials
VilleStanfordlocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT04221477
Essais cliniques associés
4| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Obinutuzumab | Lupus | Phase 3 | NCT04221477 | REGENCY — A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis | ACTIVE_NOT_RECRUITING |
| Ocrelizumab | SEP | Phase 3 | NCT04544436 | MUSETTE — A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS) | ACTIVE_NOT_RECRUITING |
| RO7121932 IV | SEP | Phase 1 | NCT05704361 | A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| Ocrelizumab | SEP | Phase 3 | NCT04548999 | GAVOTTE — A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS) | ACTIVE_NOT_RECRUITING |